Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, has formally changed its legal name from Cybin Inc. to Helus Pharma Inc., effective Oct. 1, 2026. The change was approved by shareholders at the company's annual and special meeting on Sept. 22 and follows the adoption of the Helus Pharma business name in January. This rebranding marks a significant milestone as the company positions itself for the transition from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company.
The name change is more than a cosmetic update; it aligns the company's legal identity with its strategic focus on advancing proprietary NSAs through late-stage development and toward commercialization. Helus Pharma aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. Its lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Another candidate, HLP004, is in Phase 2 for generalized anxiety disorder. These programs underscore the company's potential to bring novel treatments to market.
For investors, the name change does not affect trading. The company's common shares will continue to trade under the ticker HELP on the Nasdaq Global Market and Cboe Canada, and no action is required by existing shareholders. The continuity in ticker symbols ensures a seamless transition for the market. The rebranding may enhance visibility and better reflect the company's commercial ambitions, which could attract new investor interest.
The move comes at a time when the mental health treatment landscape is evolving, with increasing demand for innovative therapies. Helus Pharma's NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, potentially offering durable improvements in mental health. With class-leading data, the company is positioning itself as a leader in this space. The name change could also facilitate partnerships and commercial discussions as the company prepares for potential product launches.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland, and was founded in 2019. For more information, visit www.helus.com. The full press release can be viewed at https://ibn.fm/rrJFh.
MissionIR, a communications platform, disseminated the announcement. MissionIR is part of the Dynamic Brand Portfolio at IBN, which provides services such as InvestorWire for wire distribution and editorial syndication to 5,000+ outlets. These channels help companies like Helus Pharma reach a broad audience of investors and stakeholders. For more details, visit MissionIR.
The legal name change is a strategic step that underscores Helus Pharma's readiness to advance its pipeline and potentially transform mental health treatment. As the company moves closer to commercialization, its new identity may better reflect its mission and attract the attention of investors and partners in the biopharmaceutical industry.
